News
Share
In July 2020, MassBio launched an “Open Letter 2.0 – The CEO Pledge for a More Equitable and Inclusive Life Sciences Industry” calling on CEOs across the life sciences community to join and pledge toward a range of best practices designed to improve equity, diversity, inclusion, and culture inside all companies.
Together as CEOs, Captivate Bio joined other signers of this letter, which recognizes that racial inequity exists in our industry and in our companies, and we must take responsibility to fix that injustice through comprehensive equity, diversity, and inclusion initiatives that are broad in scope, specific in action, and measurable in results.
For more information about this pledge, email diversity@massbio.org or visit massbio.org to learn more.
For more information, please email diversity@massbio.org
Learn more about how we support researchers with cell culture products, contract manufacturing and storage services, custom reagent sourcing, as well as marketing, sales, and distribution programs for our industry partners.
June 2021 - Captivate Bio signs exclusive distribution agreement with PL Bioscience for of ELAREM™ human platelet lysate product lines now available in the US and Canada.
August 2025 - Captivate Bio announces the launch and availability of PLUS Human Platelet Lysate from Compass Biomedical through The Captivate Bio Access Program.
In this interview, we talk to EverCell Bio’s Philip Manos about the challenges with hPSC cultures and how ROCK Inhibitors including Captivate Bio's CET Cocktail compares to traditional methods.
